CTLA4 and cancer: Cancer patients received anti-PD-1 (nivolumab/pembrolizumab/cemiplimab, n= 112, 86%), anti-PD-L1 (atezolizumab/durvalumab, n=8, 6%), anti-CTLA-4 (ipilimumab, alone n=10; or in association with nivolumab, n=2), as first-line (n=63) or subsequent lines (n=60) of therapy (after conventional chemotherapy and/or TKI), or as adjuvant treatment (n=7).